Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.60 |
| ▸ | JAK1 | P23458 | 7/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502873 | 0.83 | PDPK1 (0.60) | JAK2PDPK1JAK3KDM4ECYP3A4 | |
| SCHEMBL10213929 | 0.78 | JAK2 (0.81) | JAK2PDPK1JAK1TYK2JAK3 | |
| SCHEMBL118573 | 0.78 | JAK2 (0.64) | JAK2PDPK1JAK1TYK2JAK3 | |
| SCHEMBL16246796 | 0.78 | JAK2 (0.48) | JAK2JAK1KDM4EFADS1 | |
| SCHEMBL30548017 | 0.78 | FADS1 (0.49) | JAK2PDPK1GAAFADS1HTR2A | |
| SCHEMBL15332567 | 0.78 | FADS1 (0.49) | JAK2PDPK1GAAFADS1HTR2A | |
| SCHEMBL13122049 | 0.78 | FADS1 (0.49) | JAK2CYP3A4GAAFADS1HTR2A | |
| SCHEMBL14095666 | 0.78 | FADS1 (0.49) | JAK2JAK1FADS1HTR2A | |
| SCHEMBL11010462 | 0.78 | FADS1 (0.49) | JAK2JAK1FADS1HTR2A | |
| SCHEMBL5510054 | 0.78 | FADS1 (0.49) | JAK2JAK1FADS1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE28939-E | MUSCLE RELAXANTS, ANALGESICS | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | claimed |
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-116023380-B | Pyrazolopyrimidine derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023071218-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 沈阳药科大学 | 2023-05-04 | — | — | WO | disclosed |
| CN-116023380-A | Pyrazolopyrimidine derivative, and preparation method and application thereof | 沈阳药科大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| CN-110818683-A | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-02-21 | — | — | CN | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-4751302-A | ANTIINFLAMMATORY, ANTIULCER AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4533731-A | ANTIINFLAMMATORY AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-08-06 | — | — | US | disclosed |
| EP-0090972-A2 | Indazole derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-10-12 | — | — | EP | disclosed |
| US-4128545-A | DISPERSE, POLYESTER | BASF AKTIENGESELLSCHAFT (DE) | 1978-12-05 | — | — | US | disclosed |
| US-4113720-A | Disperse azo dye with diaminopyrimidine coupling component | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4051252-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-4042578-A | POLYESTERS | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1977-08-16 | — | — | US | disclosed |
| US-4041025-A | FOR HYDROPHOBIC FIBERS SUCH AS POLYESTERS, YELLOW TO BLUE-GREEN SHADES | BASF AKTIENGESELLSCHAFT (DT) | 1977-08-09 | — | — | US | disclosed |
| US-3985726-A | DYEING AND PRINTING LEATHER, WOOL, SILK AND SYNTHETIC FIBERS | CIBA-GEIGY AG (CH) | 1976-10-12 | — | — | US | disclosed |
| US-RE28939-E | MUSCLE RELAXANTS, ANALGESICS | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | JAK2 167/4885PDPK1 1304/4885JAK1 317/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | JAK2 167/4885PDPK1 1304/4885JAK1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.